TDP-43 Proteinopathies clinical trials at UC Health
1 research study open to new patients
open to eligible people ages 18-80
The CENTAUR trial will be a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
at UC Irvine